where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. About HUB Organoids Holding B.V. HUB Organoids Holding ...

Merck just licensed a weight-loss drug candidate. There's reason to believe that the candidate could have a big edge. But, success is not guaranteed, and the program will take years to develop ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

BURLINGTON, Mass., December 17, 2024--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the Life Science business of ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024, despite challenges with other products. Promising future developments include ...

Doctors could have a new treatment option for protecting newborn infants from respiratory syncytial virus if the Food and Drug Administration approves Merck & Co.’s drug clesrovimab by next summer.

Merck announced on Monday that it will discontinue the development of two cancer assets, vibostolimab and favezelimab, following underwhelming Phase III data. The pharma was studying both candidates ...